Download PDF
Fortschr Neurol Psychiatr 2014; 82(10): 557-565
DOI: 10.1055/s-0034-1385108
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Stellenwert von Depotformulierungen in der Langzeittherapie der Schizophrenie

The Significance of Depot Medication in the Long-Term-Treatment of Schizophrenia
K. U. Kühn
1   Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum des Saarlandes
,
K. Wiedemann
2   Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf
,
R. Hellweg
3   Klinik für Psychiatrie und Psychotherapie, Campus Charité Mitte, Berlin
,
H. J. Möller
4   Klinik für Psychiatrie und Psychotherapie, Klinikum der Ludwig-Maximilians-Universität München
› Author Affiliations
Further Information

Publication History

Publication Date:
09 October 2014 (online)

    Permissions and Reprints

Zusammenfassung

Die Verhinderung eines Rezidivs ist das zentrale Therapieziel in der Behandlung der Schizophrenie. Jedoch erleiden schätzungsweise 75 % aller Schizophreniepatienten innerhalb von fünf Jahren ein Rezidiv. Jedes Rezidiv kann das Krankheitsbild verschlechtern und das Risiko für psychosoziale und berufliche Nachteile erhöhen. Eine kontinuierliche und langfristige Behandlung kann dieses Risiko deutlich verringern. Limitierender Faktor einer kontinuierlichen Langzeittherapie ist allerdings die Medikamenten-Adhärenz, die durch zahlreiche Faktoren beeinflusst wird. Naturalistische Studien haben gezeigt, dass Depot-Antipsychotika im Vergleich zur oralen Medikation konsistent ein besseres Outcome aufweisen, z. B. in Form einer reduzierten Rezidivrate und des Rückgangs stationärer Aufenthalte. Auch zahlreiche Metaanalysen von randomisierten kontrollierten Vergleichsstudien von Depot-Antipsychotika vs. orale Formulierungen zeigen diese Vorteile, jedoch sind die Ergebnisse nicht in allen Metaanalysen konsistent. Ergebnisse aus kontrollierten Studien spiegeln die Gegebenheiten der täglichen Praxis nicht adäquat wider. In naturalistischen Studien zeigen sich die Vorteile von Depot-Antipsychotika deutlicher. Die vorliegende Übersicht reflektiert die derzeitige Schizophrenie-Behandlung und diskutiert einen breiteren Einsatz von Depot-Antipsychotika anhand der verfügbaren Daten. Zudem werden Befürchtungen und Vorurteile von Arzt und Patient bezüglich Antipsychotika-Langzeittherapie mit Depotformulierungen erörtert und Empfehlungen für die Praxis ausgesprochen.

Abstract

Relapse prevention in schizophrenia is a key aim in therapy. However, it is estimated that approximately 75 % of patients with schizophrenia relapse within five years. Each relapse might worsen the disease and increase the risk of psychosocial and work-related disadvantages. A continuous long-term therapy is able to reduce this risk, but medical non-adherence, which is influenced by numerous factors, is a limitation. Naturalistic studies show that depot-antipsychotics compared with oral antipsychotics lead consistently to a better outcome, for example by reducing relapse rates or hospitalisation. Numerous meta-analyses of randomised controlled trials comparing oral versus depot-antipsychotics also show this advantages. However these results are not consistent in all meta-analyses. Results of controlled studies do not appropriately reflect the reality of daily practice. The advantages of depot-antipsychotics are shown more distinctly in naturalistic studies. The following review reflects the current therapy of schizophrenia and discusses adequately a broad application of depot-antipsychotics based on existing data. In addition, concerns and prejudices of physicians and patients against antipsychotic long-term therapy and depot-formulation are discussed and a recommendation is provided.

Schlüsselwörter

Schizophrenie - Rezidiv - Langzeittherapie - Medikamenten-Adhärenz - Depot-Antipsychotika

Key words

schizophrenia - relapse - longterm therapy - adherence - long acting injectable antipsychotics
 

  • Literatur

  • 1 Sheitman BB, Liebermann JA. The natural history and pathophysiology of treatment resistant schizophrenia. J Psychiatr Res 1998; 32: 143-150
    CrossrefPubMedGoogle Scholar
  • 2 Lieberman JA, Drake RE, Sederer LI et al. Science and recovery in schizophrenia. Psychiatr Serv 2008; 59: 487-496
    CrossrefPubMedGoogle Scholar
  • 3 Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187-193
    CrossrefPubMedGoogle Scholar
  • 4 Harrison G, Hopper K, Craig T et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001; 178: 506-517
    CrossrefPubMedGoogle Scholar
  • 5 Ventura J, Subotnik KL, Guzik LH et al. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res 2011; 132: 18-23
    CrossrefPubMedGoogle Scholar
  • 6 S3-Leitlinie Schizophrenie, Stand 01.11.2005. Federführende Fachgesellschaft: Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde e. V. (DGPPN).
    PubMedGoogle Scholar
  • 7 Emsley R, Nuamah I, Hough D et al. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 2012; 138: 29-34
    CrossrefPubMedGoogle Scholar
  • 8 Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962
    Google Scholar
  • 9 Hasan A, Falkai P, Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013; 14 (01) 2-44 DOI: 10.3109/15622975.2012.739708. Epub 2012 Dec 6.
    Google Scholar
  • 10 Kane JM. Schizophrenia. N Engl J Med 1996; 334: 34-41
    CrossrefPubMedGoogle Scholar
  • 11 Robinson D, Woerner MG, Alvir JMJ et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247
    CrossrefPubMedGoogle Scholar
  • 12 Leucht S, Tardy M, Komossa K et al. Antipsychottic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-2071
    Google Scholar
  • 13 Gaebel W, Jänner M, Frommann N et al. First vs. multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res 2002; 53: 145-159
    Google Scholar
  • 14 Sampson S, Mansour M, Maayan N et al. Intermittent drug techniques for schizophrenia. Cochrane Database Syst Rev. 2013; 7 CD006196 DOI: 10.1002/14651858.CD006196.pub2..
    PubMedGoogle Scholar
  • 15 Gaebel W, Reisbeck M, Wölwer W et al. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodromebased erly intervention: results of a randomized controlled trail within the German Research Network on Schizophrenia. J Clin Psychiatry 2011; 72 (02) 205-218
    CrossrefPubMedGoogle Scholar
  • 16 Wunderink L, Nieboer RM, Wiersma D et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy. JAMA Psychiatry 2013; 70 (09) 913-920
    CrossrefPubMedGoogle Scholar
  • 17 Kapur S, Zipursky R, Jones C et al. A Positron Emission Tomography Study of Quetiapine in Schizophrenia. Arch Gen Psychiatry 2000; 57: 553-559
    CrossrefPubMedGoogle Scholar
  • 18 Remington G, Kapur S. Antipsychotic Dosing: How Much but also How Often?. Schizophrenia Bulletin 2010; 36 (05) 900-903
    CrossrefPubMedGoogle Scholar
  • 19 Suzuki T, Graff-Guerrero A, Uchida H et al. Dopamine D2/3 occupancy of ziprasidone across a day: a within- subject PET study. Psychopharmacology 2013; 228: 43-51
    CrossrefPubMedGoogle Scholar
  • 20 Rabin CR, Siegel SJ. Antipsychotic dosing and drug delivery. Curr Top Behav Neurosci 2010; 4: 141-177
    PubMedGoogle Scholar
  • 21 Sheehan JJ, Reilly KR, Fu DJ et al. Comparison of the Peak-to-through Fluctuation in Plasma Concentration of Long-acting Injectable Antipsychotics and Their Oral Equivalents. Innov Clin Neurosci 2012; 9 (07) 17-23
    PubMedGoogle Scholar
  • 22 Wakamatsu A, Aoki K, Sakiyama Y et al. Predicting Pharmacokinetic Stability by Multiple Oral Administration of Atypical Antipsychotics. Innov Clin Neurosci 2013; 10 (03) 23-30
    PubMedGoogle Scholar
  • 23 Galletly CA, Foley DL, Waterreus A et al. Cardiometabolic risk factors in people with psychotic disorders: the second Australian natioanl survey of psychosis. Aust N Z J Psychiatry 2012; 46 (08) 753-761
    CrossrefPubMedGoogle Scholar
  • 24 Kern RS, Green MF, Cornblatt BA et al. The neurocognitive effects of aripiprazole: an open-lable comparison with olanzapine. Psychopharacology 2006; 187 (03) 312-320
    PubMedGoogle Scholar
  • 25 Riedel M, Spellmann I, Schennach-Wolff R et al. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia. Pharmacopsychiatry 2010; 43: 50-57
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Gründer G. Kann eine Langzeitbehandlung mit Antipsychotika zu strukturellen Hirnschäden führen?. Kontra. Nervenarzt 2013; 84: 1120-1122
    PubMedGoogle Scholar
  • 27 Ho BC, Andrearsen NC, Ziebell S et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68 (02) 128-137
    Google Scholar
  • 28 Aderholt H. Kann eine Langzeitbehandlung mit Antipsychotika zu strukturellen Hirnschäden führen?. Pro. Nervenarzt 2013; 84 (09) 1119-1118
    PubMedGoogle Scholar
  • 29 Kishimoto T, Nitta M, Borenstein M et al. Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic Review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013; 74: 957-965
    CrossrefPubMedGoogle Scholar
  • 30 Vellingan DI, Weiden PJ, Sajatovic M et al. The expert consensus guideline series: Adherence problems in patients with serios and persistant mental illness. J Clin Psychiatry 2009; (Suppl. 04) 1-46 ; quiz 47–48
    PubMedGoogle Scholar
  • 31 Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev. Neurother 2013; 13: 767-783
    CrossrefPubMedGoogle Scholar
  • 32 Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23: 637-651
    Google Scholar
  • 33 Glick ID, Stekoll AH, Hays S. The role of the family and improvement in treatment maintenance, adherence, and outcome for schizophrenia. J Clin Psychopharmacol 2011; 31: 82-85
    CrossrefPubMedGoogle Scholar
  • 34 Leucht C, Heres S, Kane JM et al. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127: 83-92
    CrossrefPubMedGoogle Scholar
  • 35 Kishimoto T, Robenzadeh A, Leucht C et al. Long-acting injectable vs. oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014; 40: 192-213
    CrossrefPubMedGoogle Scholar
  • 36 Kirson NY, Weiden PJ, Yermakov S et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013; 74: 568-575
    CrossrefPubMedGoogle Scholar
  • 37 Tiihonen J, Haukka J, Haddad PM et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168: 603-609
    CrossrefPubMedGoogle Scholar
  • 38 Offord S, Wong B, Mirski D et al. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral. J Med Econ 2013; 16: 231-239
    CrossrefPubMedGoogle Scholar
  • 39 Heres S, Hamann J, Mendel R et al. Identifying the profile of optimal candidates for antipsychotic depot therapy – a cluster analysis. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1987-1993
    Google Scholar
  • 40 Heres S, Hamann J, Kissling W et al. Attitudes of psychiatrists toward antipsychotic depot medication. J Clin Psychiatry 2006; 67: 1948-1953
    CrossrefPubMedGoogle Scholar
  • 41 Gopal S, Vijapurkar U, Lim P et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010; 25: 685-697
    PubMedGoogle Scholar
  • 42 Kane JM, Sanchez R, Perry PP et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012; 73: 617-624
    CrossrefPubMedGoogle Scholar
  • 43 Bloch Y, Mendlovic S, Strupinsky S et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?. J Clin Psychiatry 2001; 62: 855-859
    CrossrefPubMedGoogle Scholar
  • 44 Caroli F, Raymondet P, Izard I et al. Opinions of french patients with schizophrenia regarding injectable medication. Patient Prefer Adherence 2011; 5: 165-171
    PubMedGoogle Scholar
  • 45 Patel MX, De Zoysa N, Bernadt M et al. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009; 23: 789-796
    CrossrefPubMedGoogle Scholar
  • 46 Velligan DI, Wang M, Diamond P et al. Relationships among subjective and obejective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007; 58: 1187-1192
    CrossrefPubMedGoogle Scholar
  • 47 Byerly M, Fisher R, Whatley K et al. A comparison of electronic monitoring vs. clinican rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005; 133: 129-133
    CrossrefPubMedGoogle Scholar
  • 48 Lieberman JA, Alvir JM, Koreen A et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996; 14: 13S-21S
    CrossrefPubMedGoogle Scholar